Traders Buy Large Volume of GeneDx Put Options (NASDAQ:WGS)

GeneDx Holdings Corp. (NASDAQ:WGS) was the target of some unusual options trading activity on Tuesday. Investors acquired 6,604 put options on the stock. This represents an increase of 255% compared to the average daily volume of 1,861 put options.

Trending Headlines about GeneDx

Here are a few of the latest headlines about WGS:

• Positive Sentiment: GeneDx reported third-quarter EPS of $0.28, above the $0.07 consensus estimate, while revenue of $123.1 million was roughly in line with expectations. Third-quarter earnings results
• Neutral Sentiment: GeneDx said it will participate in upcoming investor conferences; the announcement did not include new financial or operating guidance. Investor conference announcement
• Negative Sentiment: Third-quarter exome and genome results rose 25%, below the company’s previously stated growth expectation of at least 29.2%. GeneDx lowered its 2026 growth target to at least 28%, raising concerns about testing-volume momentum. Article on GeneDx’s testing growth

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $1,025,002.61. Following the transaction, the chief executive officer owned 115,476 shares in the company, valued at $11,271,612.36. The trade was a 8.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the completion of the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 19,206 shares of company stock valued at $1,808,056 over the last 90 days. Insiders own 25.17% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in WGS. Strs Ohio lifted its position in shares of GeneDx by 8.7% during the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock valued at $161,000 after acquiring an additional 200 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of GeneDx by 12.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 3,300 shares of the company’s stock worth $212,000 after acquiring an additional 378 shares during the last quarter. Swiss National Bank grew its holdings in shares of GeneDx by 1.0% in the 1st quarter. Swiss National Bank now owns 40,000 shares of the company’s stock worth $2,569,000 after acquiring an additional 400 shares during the last quarter. Fifth Third Bancorp acquired a new position in shares of GeneDx in the 1st quarter worth $31,000. Finally, Keebeck Wealth Management raised its position in shares of GeneDx by 13.5% during the first quarter. Keebeck Wealth Management now owns 4,310 shares of the company’s stock worth $277,000 after purchasing an additional 513 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Performance

NASDAQ:WGS opened at $55.12 on Thursday. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87. The company has a current ratio of 4.16, a quick ratio of 3.06 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $75.23 and a 200-day moving average of $70.68. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -14.58 and a beta of 2.00.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.21. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. The company had revenue of $123.10 million for the quarter, compared to analysts’ expectations of $122.93 million. During the same quarter in the previous year, the company posted ($0.27) EPS. Analysts forecast that GeneDx will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on WGS shares. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 9th. Canaccord Genuity Group raised their target price on shares of GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Guggenheim increased their price target on GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Wall Street Zen raised GeneDx from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $90.14.

GeneDx Company Profile

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.